Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hoechst long-term diltiazem use trial planned; CCB labeling should warn of mortality risk -- HRG petition.

Executive Summary

DILTIAZEM LARGE-SCALE TRIAL TO ADDRESS CCB CONCERNS about an association between calcium channel blocker use and increased risk of cardiovascular events. In a lead-up announcement to the American Heart Association annual meeting Nov. 13-16 in Anaheim. Hoechst Marion Roussel states that it will conduct a three-year prospective study of Cardizem CD, with the intention of finding "definitive answers about the long-term effects of Cardizem CD in treating high blood pressure."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel